不同剂型沙美特罗替卡松粉吸入剂治疗中度哮喘的疗效评估  

The therapeutic effect of Seretide inhalation with different type on moderate bronchial asthma

作　　者：罗虹[1] 

机构地区：[1]四川省人民医院保健科,成都610072

出　　处：《疑难病杂志》2008年第9期525-527,共3页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的观察2种不同剂型的沙美特罗替卡松粉吸入剂(舒利迭)治疗中度持续哮喘的效果。方法将100例中度持续哮喘患者随机分成2组,分别使用舒利迭50/250(对照组)及舒利迭50/500(治疗组)治疗12周,治疗前后观察临床症状的改变、哮喘控制的时间以及肺功能(PEF、PEF%、FEV1、FEV1%)的改变。结果2组治疗后临床症状评分均有显著改善,治疗组总有效率(96.0%)明显高于对照组(86.0%)(P<0.05),PEF、PEF%、FEV1和FEV1%亦有显著提高(P<0.05),且治疗组优于对照组,差异有统计学意义(P<0.05)。对照组哮喘部分控制时间(24.7d±1.3d)和完全控制时间(46.7d±1.5d)与治疗组部分控制时间(16.9d±1.7d)、完全控制时间(38.8d±1.8d)比较,差异有统计学意义(P<0.05)。结论应用舒利迭治疗中度持续哮喘能迅速改善临床症状和肺功能,在治疗的初始阶段,舒利迭50/500比舒利迭50/250能更快地缓解症状,从而缩短病程。Objective To observe the clinical effect of Seretide inhalation on patients with moderate bronchial asthma,and to compare different dose of seretide inhalation(50/500 and 50/250).Methods One hundred patients with moderate bronchia asthma were randomly divided into two groups treated with Seretide 50/250 and Seretide 50/500 lasted for 12 weeks.The pulmonary function(PEF,PEF%,FEV,FEV1%)and clinical symptom were monitored in two groups before and after the treatment.Results The clinical symptoms were obviously...

关 键 词：舒利迭 哮喘 中度 肺功能 

分 类 号：R562.25[医药卫生—呼吸系统]